QUOTE AND NEWS
Benzinga  Oct 14  Comment 
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq: SCMP), a global biopharmaceutical company, today announced that it signed on October 9, 2014 an amendment to the existing collaboration and license agreement (Collaboration Agreement) covering the...
FiercePharma  Oct 10  Comment 
Turning the ancient gout remedy colchicine into an FDA-approved drug may not have been as costly an endeavor as developing a new med from scratch. But Takeda Pharmaceuticals still wants to reap brand-level sales for its version, dubbed...
StreetInsider.com  Oct 9  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sucampo+Pharma+%28SCMP%29%2C+Takeda+Enter+Settlement%2C+Licensing+Arrangement+with+Anchen+Pharma/9901043.html for the full story.
FiercePharma  Oct 3  Comment 
Lawyers in another Actos failure-to-warn trial claimed the company put profits ahead of patient safety, by keeping mum on study data that flagged links between the diabetes drug and cancer.
GenEng News  Sep 30  Comment 
Four months after starting to co-develop the preclinical autoimmune compound MGD010, Takeda Pharmaceutical and MacroGenics have launched an up-to-$1.6 billion-plus expansion of their collaboration by agreeing to develop four additional drugs based...
FierceBiotech  Sep 29  Comment 
Four months after it signed an option pact that included $33 million in an upfront and early milestone, along with $468 million in add-on incentives, Takeda has agreed to pay the freight on researching up to four more MacroGenics programs while...
DailyFinance  Sep 29  Comment 
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced that patients with Hodgkin lymphoma (HL) who received ADCETRIS (brentuximab vedotin) as consolidation therapy...
StreetInsider.com  Sep 29  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sucampo+Pharma+%28SCMP%29%2C+Takeda+Launch+AMITIZA+D-t-C+Ad+Campaign/9865689.html for the full story.




 
TOP CONTRIBUTORS

No more s***. All posts of this qaultiy from now on

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki